SB 195 would authorize the Department of Mental Health and Addiction Services, in consultation with the Department of Public Health, to create a pilot program for overdose prevention centers in up to four municipalities, subject to local approval. These centers would provide harm-reduction and treatment-related services such as counseling, drug-checking test strips, referrals to substance use disorder treatment, basic support services, and supervised consumption of controlled substances by licensed health care providers who can intervene in the event of an overdose. The bill also gives participating providers civil and criminal liability protection for administering opioid antagonists in the pilot program and shields their participation from professional discipline under specified licensing provisions.
The bill further directs the commissioner to convene an advisory committee, if established, with representatives from public health, medicine, hospitals, addiction medicine, law enforcement, municipalities, academia, harm reduction, and people with lived experience. That committee would recommend ways to maximize public health and safety, address disposal of syringes and paraphernalia, support recovery services, identify legal issues affecting the centers, and advise licensing boards. DMHAS may adopt regulations to implement the pilot and must report to the legislature by January 1, 2028 on the pilot and any recommendation for permanent authorization. The bill also prohibits the use of state funds for the pilot, while allowing private donations and grants to support it.
In addition, SB 195 amends the state’s certificate-of-need law to exempt the establishment of overdose prevention centers, and also harm reduction centers established under a separate pilot program, from CON review. This places the proposed centers alongside other categories of health care facilities and services that do not require prior state approval for expansion or establishment. The bill therefore changes both public health policy and health facility regulation by creating a new, narrowly defined pathway for supervised overdose prevention services and by removing a regulatory barrier to their operation.
The overall sentiment reflected in the voting history is supportive but not unanimous. The bill received joint favorable action in the Public Health Committee and later in the Appropriations Committee, with both committees approving it by clear margins. That pattern suggests meaningful legislative support for a harm-reduction approach to overdose prevention and treatment access, while still indicating some opposition.
The main point of contention is the concept of supervised consumption itself. Supporters appear to view the pilot as a public health response to accidental overdose deaths, with added pathways to treatment and recovery. Opponents likely focus on concerns about legality, public safety, neighborhood impacts, and whether the state should authorize facilities where controlled substances are consumed under supervision. The bill’s inclusion of law enforcement, municipal, medical, and harm-reduction voices on the advisory committee suggests lawmakers anticipated those concerns and sought to balance them in the pilot design.
SB 195 would add a new section to the general statutes authorizing a DMHAS-led overdose prevention center pilot in up to four municipalities and would amend the certificate-of-need statute, CGS § 19a-638(b), to exempt overdose prevention centers and related harm reduction centers from CON review. It would also create liability and disciplinary protections for participating licensed health care providers and allow the state to implement the pilot through regulations, reporting, and private funding rather than state appropriations.
The bill appears to have broad committee support, having received joint favorable votes in both Public Health and Appropriations, but not without opposition. The vote tallies show a clear majority in favor in each committee, indicating generally positive sentiment toward overdose prevention and treatment access, while the presence of substantial nays suggests the proposal remains controversial.
The central controversy is whether Connecticut should authorize supervised consumption sites as a harm-reduction strategy. Supporters emphasize overdose prevention, linkage to treatment, and public health benefits, while opponents are likely concerned about enabling drug use, legal liability, public safety, and local community impacts. There is also likely debate over the role of municipalities in approving sites, the use of private versus state funding, and whether the state should exempt these facilities from certificate-of-need review.